NO20065271L - Sammensetninger innbefattende alfa-2-delta ligander - Google Patents

Sammensetninger innbefattende alfa-2-delta ligander

Info

Publication number
NO20065271L
NO20065271L NO20065271A NO20065271A NO20065271L NO 20065271 L NO20065271 L NO 20065271L NO 20065271 A NO20065271 A NO 20065271A NO 20065271 A NO20065271 A NO 20065271A NO 20065271 L NO20065271 L NO 20065271L
Authority
NO
Norway
Prior art keywords
compositions including
including alpha
delta ligands
pain
alpha
Prior art date
Application number
NO20065271A
Other languages
English (en)
Norwegian (no)
Inventor
Laurent Pascal Audoly
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20065271L publication Critical patent/NO20065271L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO20065271A 2004-04-20 2006-11-16 Sammensetninger innbefattende alfa-2-delta ligander NO20065271L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56386304P 2004-04-20 2004-04-20
PCT/IB2005/000935 WO2005102389A2 (en) 2004-04-20 2005-04-08 Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists

Publications (1)

Publication Number Publication Date
NO20065271L true NO20065271L (no) 2006-12-12

Family

ID=34962978

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065271A NO20065271L (no) 2004-04-20 2006-11-16 Sammensetninger innbefattende alfa-2-delta ligander

Country Status (16)

Country Link
US (1) US20090036495A1 (ja)
EP (1) EP1740211A2 (ja)
JP (1) JP2007533723A (ja)
KR (1) KR20070000495A (ja)
CN (1) CN1946391A (ja)
AR (1) AR049029A1 (ja)
AU (1) AU2005235248A1 (ja)
BR (1) BRPI0509993A (ja)
CA (1) CA2563356A1 (ja)
IL (1) IL178609A0 (ja)
MX (1) MXPA06012172A (ja)
NO (1) NO20065271L (ja)
RU (1) RU2006137076A (ja)
TW (1) TW200539861A (ja)
WO (1) WO2005102389A2 (ja)
ZA (1) ZA200608738B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0934061T1 (en) 1996-07-24 2003-10-31 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
CA2613522A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
EP2025672B1 (en) * 2006-05-31 2013-09-18 Daiichi Sankyo Company, Limited Process for producing 1-carbamoyl-3,7-dioxo-1,4-diazepane compounds
AU2007283404B2 (en) * 2006-08-11 2013-04-18 Merck Canada Inc. Thiophenecarboxamide derivatives as EP4 receptor ligands
US8598355B2 (en) * 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
CA2754702C (en) * 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
CA2789665C (en) * 2010-02-22 2020-06-16 Raqualia Pharma Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
CN107496421A (zh) * 2013-03-19 2017-12-22 株式会社ＡｓｋＡｔ Ep4受体拮抗剂在软骨疾病的治疗中的用途
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
MA38661A1 (fr) 2013-06-27 2017-03-31 Pfizer Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
CA2941008C (en) * 2014-03-06 2022-07-26 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
US10239885B1 (en) * 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
EP3820469A4 (en) * 2018-07-11 2022-04-13 Arrys Therapeutics, Inc. EP4 INHIBITORS AND USE THEREOF
US11254675B2 (en) * 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2206119C (en) * 1994-12-12 2008-05-13 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1202730B1 (en) * 1999-08-10 2004-08-04 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of neuropathic pain
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0031295D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
HUP0400183A2 (hu) * 2001-06-11 2004-07-28 Xenoport Inc. Gaba-analóg prodrugok csökkentett toxicitású orális dózisformái

Also Published As

Publication number Publication date
US20090036495A1 (en) 2009-02-05
RU2006137076A (ru) 2008-04-27
WO2005102389A2 (en) 2005-11-03
CA2563356A1 (en) 2005-11-03
JP2007533723A (ja) 2007-11-22
WO2005102389A9 (en) 2009-04-30
AR049029A1 (es) 2006-06-21
BRPI0509993A (pt) 2007-10-16
CN1946391A (zh) 2007-04-11
TW200539861A (en) 2005-12-16
KR20070000495A (ko) 2007-01-02
WO2005102389A3 (en) 2006-08-17
EP1740211A2 (en) 2007-01-10
MXPA06012172A (es) 2007-01-17
IL178609A0 (en) 2007-02-11
ZA200608738B (en) 2008-06-25
AU2005235248A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
NO20065271L (no) Sammensetninger innbefattende alfa-2-delta ligander
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
IL210916A (en) Clonidine and medicinal products containing it for the prevention or treatment of mucosal inflammation
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
IL209121A (en) Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases
WO2009121872A3 (en) Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
MY157716A (en) Solid dosage form of olmesartan medoxomil and amlodipine
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
DK2012764T3 (da) Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
BRPI0817275A2 (pt) Combinação farmacêutica de alisquireno e valsartana
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
WO2009032843A3 (en) Deuterated ethambutols and their use
MX2009005798A (es) Recuperacion de apoplejia.
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
JO2773B1 (en) 2-oxo-alkyl-1-piprazine-2-1 derivatives, their preparation and therapeutic use.
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
EP4218786A3 (en) Opiorphin for use as analgesic agent
TR201901012T4 (tr) Arteriosklerozun tedavisinde nor-safra asitlerinin kullanımı.
WO2007108004A8 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
WO2006042277A3 (en) Extended release compositions of proton pump inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application